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INTRODUCTION
Indwelling central venous catheters (CVCs) have the potential 
to cause bloodstream infections, and the prevention of central 
line-associated bloodstream infections (CLABSIs) can reduce 
adverse outcomes, such as excessive medical costs, risk of 
mortality, and long-term hospitalization.1-3 For these reasons, 
the importance of catheter management is emphasized through-
out the literature.4-8
In our hospital, a tertiary center in South Korea, the incidenc-
es of CLABSIs in patients of the intensive care unit (ICU) were 
4.8 episodes per 1000 catheter days in 2008, 5.9 in 2009, and 7.8 
in 2010. These values remain higher than those of other hos-
pitals of similar scale.9
After providing new updated prevention guidelines in 2011 
for intravascular catheter-related infections,10 working groups, 
including the Centers for Disease Control and Prevention 
(CDC), emphasized the importance of educating and training 
health care personnel in CVC placement, namely using maxi-
mal sterile barrier precautions (MBPs), chlorhexidine skin prep-
aration, avoiding the femoral vein as an access site, avoiding 
routine replacement of CVCs, and using antiseptic/antibiotic 
impregnated short-term CVCs when inserting CVCs. Based 
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Purpose: The present study aimed to evaluate the effect of central line (CL) bundle compliance on central line-associated blood-
stream infections (CLABSIs) in different departments of the same hospital, including the intensive care unit (ICU) and other de-
partments.
Materials and Methods: The four components of the CL bundle were hand hygiene, use of maximal sterile barrier precautions, 
chlorhexidine use, and selection of an appropriate site for venous access. Compliance of the CL bundle and CLABSIs were mea-
sured for every department [emergency room (ER), ICU, general ward (GW), and operating room (OR)]. A total of 1672 patients 
were included over 3 years (August 2013 through July 2016).
Results: A total of 29 CLABSI episodes (1.73%) were identified, and only 53.7% of the patients completed CL bundles. The perfor-
mance rates of all components of the CL bundle were 22.3%, 28.5%, 36.5%, and 84.6% for the ER, ICU, GW, and OR, respectively. 
The highest CLABSI rate was observed in patients of the ICU, for whom all components were not performed perfectly. Conversely, 
the lowest CLABSI rate was observed for patients of GWs, for whom all components were performed. Among individual compo-
nents, femoral insertion site [relative risk (RR), 2.26; 95% confidence interval (CI), 1.09−4.68], not using a full body drape (RR, 3.55; 
95% CI, 1.44−8.71), and not performing all CL bundle components (RR, 2.79; 95% CI, 1.19−6.54) were significant variables associ-
ated with CLABSIs.
Conclusion: This study provides direct evidence that completing all CL bundle components perfectly is essential for preventing 
CLABSIs. Customized education should be provided, according to specific weaknesses of bundle performance.
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on these guidelines, we previously began using chlorhexidine 
and antiseptic impregnated CVCs,11,12 and in 2012, we modi-
fied our in-hospital instructions related to MBPs.
The most recent studies that have reported improvements 
in CLABSI rates have drawn their comparisons from data be-
fore and after specific interventions and have primarily tar-
geted patients of the ICU.13-20 In the studies that have included 
patients who were not from the ICU, only certain parts of the 
central line (CL) bundle had been included in the reported an-
alyses.21-23 To address these limitations, we evaluated CLABSIs 
according to the rates of completion of CL bundle components, 
rather than performing a comparison of rates before and after 
the intervention. In addition, we investigated CLABSI rates for 
multiple departments, including the ICU, general ward (GW), 
emergency room (ER), and operating room (OR).
The aim of this study was to evaluate the direct effect of com-
pleting all CL bundle components on CLABSI rates, according 
to the department, after modifying our in-hospital instruc-
tions based on updated prevention guidelines.10 In addition, we 
sought to identify commonalities among weak areas of CL bun-
dle performance between departments. To the best of our 
knowledge, this is the first study to evaluate rates of CL bundle 
performance and CLABSIs according to individual hospital 
departments.
 
MATERIALS AND METHODS
Study populations and CL bundle components
Data were collected over 3 years (from August 2013 through 
July 2016) from patients who underwent new CVC insertions 
during the first week of every month. Patients less than 2 years of 
age or those with missing data were excluded from the study.
We measured CL bundle performance compliance accord-
ing to a check list based on CDC guidelines.10 Among the CL 
bundle components, education and training were conducted 
uniformly for all medical personnel at our hospital.24 Educa-
tion and training for infection control were conducted at least 
twice a year. We regularly promoted the CVC insertion and 
maintenance guidelines through e-mail. The missing bundle 
result was sent immediately to the physician who inserted the 
catheter by mobile text message, and bundle performance 
check list feedback was reported to the senior staff. Likewise, 
antimicrobial/antiseptic-impregnated catheters were used 
exclusively during the study period. 
CL bundle performance monitoring consisted of the follow-
ing four components: hand hygiene, use of MBPs, use of 
chlorhexidine skin preparation, and selection of an appropri-
ate site for central venous access. All CVC catheters were in-
serted by a skilled physician, and a third-person nurse, who 
was not an assistant nurse, reviewed the checklist at the time 
of catheter insertion.
 
Definitions
We defined bloodstream infection (BSI) as newly developed 
primary BSIs without definite evidence of another infection 
based on the United States National Healthcare Safety Network 
(NHSN) system.25 In cases where blood cultures were positive 
for normal skin flora, the identification of the offending organ-
ism was based on at least two pairs of blood cultures and the 
presence of at least one of the following clinical symptoms: fe-
ver, chills, or hypotension. The CVC must have been present for 
at least two additional days, and the CLABSI was defined as 
the present CVC on either the date when the BSI occurred or the 
day before the BSI occurred, according to the Korean Nosoco-
mial Infections Surveillance System (KONIS) definition.26,27 
Catheter day was calculated as the interval between catheter 
removal and insertion dates, and the CLABSI rate was expressed 
as the number of CLABSI episodes per 1000 catheter days (Epi-
sodes of CLABSI/total sum of catheter day×1000). We reviewed 
electrical medical records up to 48 hours after CVC removal.
Central venous catheter
We used the ARROW® central venous catheterization set for 
this study (ARROWg+ard Blue® Catheter with Blue FlexTip®, 
ARROW International Inc., Reading, PA, USA). Catheters un-
derwent external surface treatment using sulfa antimicrobials, 
chlorhexidine acetate, and sulfadiazine.
Ethics statement
The protocol for this retrospective study was reviewed and ap-
proved by the Institutional Review Board at the Gangnam Sev-
erance Hospital of the Yonsei University Health System in Seoul, 
Korea (Reg. No. 3-2017-0043). The board waived the require-
ment for informed consent. All procedures were conducted in 
accordance with the guidelines of the Declaration of Helsinki.
Statistical analysis
Statistical analyses were performed using SPSS statistics, ver-
sion 23 (IBM Corp., Armonk, NY, USA). Categorical variables 
are expressed as the frequency and number of CLABSI epi-
sodes per 1000 catheter days. Statistical differences among in-
fection rate trends were analyzed using the chi square test. 
Comparative analysis with the Poisson regression test was used 
to identify the most important factors associated with CLABSI 
rates. Results are described as relative risk (RR) with 95% con-
fidence intervals (CIs). p-values <0.05 were considered statis-
tically significant.
RESULTS
Overall CLABSI rates according to CL bundle 
performance rates
A total of 1672 patients (ICU, n=371; ER, n=376; OR, n=769; GW, 
n=156) were enrolled over the 3-year study period, and the me-
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dian length of catheterization was 6.0 [interquartile range (IQR) 
3−12] days. Our analysis included a total of 14829 catheter-days, 
of which we identified 29 (1.73%) CLABSI episodes. All four 
components of the CL bundle were performed on a total of 898 
(53.7%) patients, while one or more components of the CL 
bundle were omitted for 774 (46.3%) patients. Among patients 
for whom all four components of the CL bundle were per-
formed, there were 7 (0.77%) CLABSI episodes, with a CLABSI 
rate of 1.0. On the other hand, there were 22 (2.84%) CLABSI 
episodes among patients who missed a component of the CL 
bundle, with a resulting CLABSI rate of 2.80 (p=0.013) (Table 1).
Performance rates of each component of the CL 
bundle according to department
The department-specific rates of performance for each com-
ponent of the CL bundle are shown in Fig. 1. Notably, the per-
centage of non-femoral site insertions was 35.8% in patients 
admitted to ICUs, and the percentage of full MBP compliance 
was only 27.9% in patients admitted to the ER. The percentages 
of patients for whom all four components of the CL bundle 
were performed were 22.3%, 28.5%, and 36.5% for the ER, 
ICU, and GW cohorts, respectively. Conversely, for the OR co-
hort, the rate of total compliance with the CL bundle compo-
nents was 84.6% (Table 1).
Department-specific CLABSI rates according to CL 
bundle performance
In the ICU, 1.8% of patients who underwent all four compo-
nents of the CL bundle had a CLABSI, with a resulting CLABSI 
rate of 1.45. On the other hand, 4.9% of patients for whom one 
or more components of the CL bundle were omitted had a 
CLABSI, with a resulting CLABSI rate of 3.73 (p=0.197). A sim-
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Fig. 1. Performance of each component of the CL bundle by individual department. Bars represent the rates for hand washing, use of chlorhexidine, 
selection of a non-femoral insertion site, performing all components of MBPs, and performing all components of the CL bundle. The CL bundle consists 
of four components: hand hygiene, use of MBPs, use of a chlorhexidine skin preparation, and selection of an appropriate site for central venous ac-
cess. MBP, maximal sterile barrier precaution; CL, central line; ICU, intensive care unit; ER, emergency room; OR, operating room; GW, general ward.
Table 1. CLABSI Rates According to Performance of the CL Bundle
Department CL bundle* Performance CLABSI episodes Catheter day CLABSI rate p value
Total
4 898 (53.7)   7/898 (0.77) 6980 1.00
0.013
0−3 774 (46.3) 22/774 (2.84) 7849 2.80
ICU (n=371)
4 106 (28.5)   2/106 (1.8) 1378 1.45
0.197
0.120
0−3 265 (71.4) 13/265 (4.9) 3488 3.73
ER (n=376)
4   84 (22.3)     1/84 (1.1) 671 1.49
0.696
0−3 292 (77.6)   5/292 (1.7) 2195 2.28
OR (n=769)
4 651 (84.6)   4/651 (0.6) 4099 0.98
0.901
0−3 118 (15.3)   1/118 (0.8) 892 1.12
GW (n=156)
4   57 (36.5)     0/57 (0) 832 0.00
0.161
0−3   99 (63.4)     3/99 (3.0) 1274 2.35
CL, central line; CLABSI, central line associated blood stream infection; ICU, intensive care unit; ER, emergency room; OR, operating room; GW, general ward.
Data are expressed as frequencies (percentages). The CLABSI rate is expressed as the number of CLABSI episodes per 1000 catheter days (episodes of CLABSI / 
total sum of catheter days×1000). 
*Number of performed components of the CL bundle. The CL bundle consists of four components: hand hygiene, use of maximal sterile barrier precautions, use 
of a chlorhexidine skin preparation, and selection of an appropriate site for central venous access. 
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ilar trend was noted for patients of the ER (CLABSI episodes; 
1.1% vs. 1.7%, CLABSI rates; 1.49 vs. 2.28, p=0.696), patients of 
the OR (0.6% vs. 0.8%; 0.98 vs. 1.12; p=0.901), and patients of 
the GW (0% vs. 3.0%, 0 vs. 2.35, p=0.161). In general, CLABSI 
rates were highest in patients for whom one or more compo-
nents of the CL bundle were not performed; however, among 
this subset of patients, there were no significant differences in 
CLABSI rates between departments (Table 1).
CLABSI rates according to performance of individual 
CL bundle components
We next examined CLABSI rates according to the perfor-
mance of each component of the CL bundle (Table 2). The 
CLABSI rate was lower in patients for whom complete hand 
washing than in patients for whom hand washing was not 
performed (1.89 vs. 3.94, p=0.304). Similarly, the CLABSI rate 
was lower in patients for whom 2% chlorhexidine was used 
compared to patients for whom another disinfectant was used 
(1.86 vs. 3.66, p=0.255). The CLABSI rate was also lower in pa-
tients with a non-femoral catheter insertion site than in pa-
tients with a femoral catheter (1.39 vs. 3.15, p=0.024). For this 
study MBPs consisted of five components, including a mask, 
gown, hat, gloves, and full drape. The CLABSI rate was lower 
in patients for whom at least four of the five MBP components 
was used than in patients for whom zero to three of the five 
MBP components were used (1.56 vs. 3.81, p=0.018).
Relative risk for variables associated with CLABSIs
Lastly, the four components of the CL bundle were analyzed 
using the Poisson regression test. Among the bundle compo-
nents, it was necessary to exclude gloves from the MBP analy-
sis, which otherwise consists of a mask, gown, gloves, hat, and 
full drape, as no CLABSIs occurred among the four cases where 
gloves were not used (Supplementary Table 1, only online). An 
insertion site in the femoral area [RR, 2.26 (95% CI, 1.09−4.68); 
p=0.028], not using a full drape [RR, 3.55 (95% CI, 1.44−8.71); 
p=0.006], use of only zero to three MBP components [RR, 2.44 
(95% CI, 1.13−5.25); p=0.022], and not performing all four 
components of the CL bundle [RR, 2.79 (95% CI, 1.19−6.54); 
p=0.018] were identified as significant variables associated 
with an increased risk of CLABSIs (Table 3).
Table 2. CLABSI Rates According to Performance of Each Component of the CL Bundle
CL bundle Performance CLABSI episodes Catheter day CLABSI rate p value
Hand washing
(+) 27/1606 (1.6) 14321 1.89
0.304
(-)       2/66 (3.0) 508 3.94
Disinfectant
2% CHG 26/1596 (1.6) 14010 1.86
0.255
Others       3/76 (3.9) 819 3.66
Insertion site
Non-femoral 14/1260 (1.1) 10065 1.39
0.024
Femoral   15/412 (3.6) 4764 3.15
MBP*
4−5 19/1364 (1.3) 12202 1.56
0.018
0−3   10/308 (3.2) 2627 3.81
CL, central line; CLABSI, central line associated blood stream infection; CHG, chlorhexidine gluconate; MBP, maximal sterile barrier precaution.
Data are expressed as frequencies (percentages). The CLABSI rate is expressed as the number of CLABSI episodes per 1000 catheter days (episodes of CLABSI / 
total sum of catheter days×1000). 
*Number of components of MBPs performed, consisting of mask, gown, glove, hat, and full drape. 
Table 3. RR for Variables of CLABSIs 
Variable Performance RR (95% CI) p value
CL bundle
Hand washing (-)/(+) 2.08 (0.49−8.78) 0.315
Disinfectant Others/CHG 1.97 (0.59−6.52) 0.265
Insertion site Femoral/non-femoral 2.26 (1.09−4.68) 0.028
MBP
Mask (-)/(+) 2.37 (0.96−5.82) 0.059
Gown (-)/(+) 1.30 (0.53−3.20) 0.563
Hat (-)/(+) 1.92 (0.87−4.22) 0.104
Full drape (-)/(+) 3.55 (1.44−8.71) 0.006
MBP* 0−3/4−5 2.44 (1.13−5.25) 0.022
CL bundle* 0−3/4 2.79 (1.19−6.54) 0.018
CLABSI, central line associated blood stream infection; RR, relative risk; CI, confidence interval; MBP, maximal sterile barrier precaution; CHG, chlorhexidine glu-
conate; CL, central line.
*Number of components of MBPs and CL bundles performed. MBPs consist of a mask, gown, glove, hat, and full drape. The CL bundle consists of four components: 
hand hygiene, use of maximal sterile barrier precautions, use of a chlorhexidine skin preparation, and selection of an appropriate site for central venous access. 
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DISCUSSION
While many previous studies on CLABSIs have focused on 
patients of the ICU,13-19 we also included patients from non-
ICU departments in the present study. In addition, we ana-
lyzed individual components of the CL bundle, including the 
five components of MBP. The performance rate for complet-
ing all four components of the CL bundle was 53.7%, which 
was lower than expected, based on previously reported rates 
of 60−80%.28-30 The performance rate for the CL bundle, when 
including cases where only one component was omitted, was 
90.4%. However, post-hoc analysis showed that the CLABSI 
rates for cases wherein only three of the four CL bundle com-
ponents were used, as well as in cases where only zero to two 
of the four components were used, were both twice as high as 
cases wherein all components of the CL bundle were used 
(Supplementary Table 2, only online). Therefore, in contrast 
to previous studies showing that CLABSI rates are reduced by 
partial compliance with the CL bundle,14,21 our results suggest 
that physicians should perform all aspects of the CL bundle 
completely and without exception. 
According to individual departments, the CLABSI rate was 
the highest among patients in the ICU, where all components 
of the CL bundle were not performed perfectly, and the CLABSI 
rate was zero for patients of the GW, where all components of 
the CL bundle were performed. With respect to each compo-
nent of the CL bundle, hand washing was generally performed 
well in all departments, especially in the OR, for 100% of pa-
tients. The performance rate of chlorhexidine skin prepara-
tion was relatively low in patients of the GW, compared to other 
departments, which was thought to be due to insufficient prep-
aration and dissemination of information. The reason for the 
use of a femoral insertion site, which was most prevalent in 
patients of the ICU, was likely due to the ease of this approach 
for patients who were immobile and the desire to reduce the 
risk of pneumothorax.6,31 However, many previous studies have 
shown that the femoral approach is associated with a higher 
risk of CLABSIs, compared to subclavian or internal jugular 
approaches.6,31-33 Thus, the continued education of physicians 
to avoid femoral access for infection control over convenience 
of insertion is necessary. Lastly, the performance rate for MBPs 
was significantly lower in patients of the ER, compared to those 
in other departments.
Notably, among individual components of MBPs, the rate 
of gown (36.4%) and hat (30.8%) use was lower than the other 
MBP components. Indeed, the performance rate for using ster-
ile gloves was 100% in all hospital departments except the ER, 
although the performance rate of this department was still 
relatively high (98.9%) compared to other MBP components 
(Supplementary Table 1, only online). In contrast, with respect 
to the overall performance rate of the entire CL bundle, the 
rate of compliance of patients of the OR was very high (84.6%). 
This result likely reflects characteristics of the OR department, 
which is sensitive to infection control. Based on these results, 
we believe that a customized strategy and education plan to 
address department-specific weakness will be useful (Fig. 1, 
Table 1).
The CLABSI rate according to individual components of the 
CL bundle confirmed that the site and use of MBPs were sig-
nificant factors. Among the individual components of MBPs, 
failure to use a full drape carried the highest risk of CLABSI. 
Therefore, it is important to approach a non-femoral site6,31-33 
when inserting a CVC and to always use MBPs,22,34,35 especially 
a full body, sterile drape. Furthermore, it is important to make 
efforts to perform all aspects of the CL bundle, as doing so re-
duces the rate of CLABSIs.
There were some limitations to this study. First, there were 
very few CLABSI episodes (n=29) among the 1672 patients who 
were enrolled in this study. Owing to this low event rate, there 
were possibly no significant differences in CLABSI rates ac-
cording to CL bundle performance. Thus, larger-scale studies 
that are capable of evaluating more CLABSI episodes will be 
necessary. On the other hand, because infection management 
has now become an apparent strength of our hospital, after 
modifying our in-hospital instructions and education in 2012, 
our results can serve as a baseline for comparison with other 
institutions and departments. A second limitation of this study 
was the relationship between variables. For example, a full 
drape was one of the components of MBPs, while MBPs were 
themselves a component of the CL bundle. Therefore, since 
many of the study variables were related to each other, a multi-
variate analysis could not be performed. A third limitation was 
that the factors that may affect CLABSI rates, such as severity 
of diseases, catheterization days, removal of unnecessary cath-
eter, and catheter maintenance care, were not investigated. 
The median catheterization time in patients for whom the bun-
dle was performed perfectly was 5.0 (IQR 3−9) days, while this 
duration was 7.0 (IQR 3−14) days in patients for whom at least 
one or more components of the CL bundle was not performed. 
This difference can affect the CLABSI rate, and we focused on 
the CL ‘insertion’ bundle rather than CL ‘maintenance’ bun-
dle. These factors should be investigated in future studies.
During the 3-year period, we monitored physicians who in-
serted CVCs using checklists and provided feedback through 
mobile texts and e-mails. If the CVC was inserted at the femo-
ral site in the ICU or if a gown and hat were not used in the ER, 
immediate feedback should be provided, and CLABSI rates 
can be improved through department-customized training.
In conclusion, the results of this study provide direct evi-
dence that completing all components of the CL bundle per-
fectly in each patient is essential for preventing CLABSIs. Our 
results support the possibility that infection prevention can be 
improved through customized education and training of each 
department, according to individual areas of weak CL bundle 
performance.
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